Les Hopitaux De Chartres

Les Hopitaux De Chartres is conducting studies focused on cardiovascular disease and metabolic conditions, aiming to evaluate new therapies that reduce heart attacks, strokes, and improve kidney outcomes.

• Evaluation of novel lipid‑lowering agents
• Combination therapy for heart failure with preserved ejection fraction
• Impact of weight management on cardiovascular risk

These trials include patients with atherosclerotic cardiovascular disease, high lipoprotein(a), and type 2 diabetes, seeking to lower major adverse cardiovascular events.

Research in the intensive care unit addresses acute respiratory failure, chronic obstructive pulmonary disease, and ventilator‑associated pneumonia, testing interventions that improve oxygenation and reduce infection.

• Optimizing ventilatory strategies for hypoxemic patients
• Evaluating antimicrobial stewardship for ventilator‑associated pneumonia
• Assessing inhaled triple therapy in COPD

The goal is to enhance survival and shorten intensive care stays for patients with severe lung disease and critical illness.

The department supports trials targeting multiple myeloma, gastrointestinal cancers, and solid tumors, focusing on therapies that increase remission rates and prolong disease‑free survival.

• Minimal residual disease driven treatment adaptation in myeloma
• Adjuvant chemotherapy for ampullary adenocarcinoma
• Combination regimens for pancreatic adenocarcinoma

Patients receive cutting‑edge immunotherapies and targeted agents to improve outcomes in high‑risk malignancies.

Studies explore the management of ANCA‑associated vasculitis and rheumatoid arthritis, testing strategies that reduce reliance on long‑term immunosuppression.

• Immunosuppression discontinuation in vasculitis with renal involvement
• Rituximab dose optimization for rheumatoid arthritis
• IL‑6 inhibition to lower cardiovascular inflammation

These investigations aim to maintain disease control while minimizing adverse effects of chronic therapy.

Clinical work includes trials on bacterial infections and viral lung disease, evaluating approaches that enhance treatment effectiveness and limit antibiotic overuse.

• Stewardship protocol for ventilator‑associated pneumonia
• Tozorakimab as adjunct in viral lung infection
• Corticosteroid use in septic arthritis

Outcomes focus on mortality, infection resolution, and prevention of resistant organisms.

The anesthesiology team investigates optimal drug regimens for rapid sequence induction and postoperative comfort, aiming to reduce complications during surgery.

• Ketamine versus propofol for first‑attempt intubation
• Continuous lidocaine infusion after major abdominal surgery
• Analgesic strategies to lower opioid side effects

Research supports evidence‑based protocols that improve patient safety and recovery in the operating room.

Advanced imaging and biomarker studies are integrated into trials to better predict disease progression and treatment response.

• Coronary CT angiography to assess non‑calcified plaque
• Cardiac MRI for myocardial inflammation in myocarditis
• Lipoprotein(a) measurement guiding lipid‑lowering therapy

These tools help personalize therapy across cardiovascular, oncologic, and inflammatory conditions.